Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Cancer Research

• Publication date

  1998-04-15

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 9563495
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Allele‐specific detection of K‐ras oncogene expression in human non‐small‐cell lung carcinomas

  2007cited by this paper
• The Geranylgeranyltransferase-I Inhibitor GGTI-298 Arrests Human Tumor Cells in G0/G1 and Induces p21WAF1/CIP1/SDI1 in a p53-independent Manner*

  1997cited by this paper
• Farnesyltransferase Inhibitors Alter the Prenylation and Growth-stimulating Function of RhoB*

  1997cited by this paper
• GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells.

  1997cited by this paper
• Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines

  1997cited by this paper
• Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts.

  1996cited by this paper
• Single somatic ras gene point mutation in soft tissue malignant fibrous histiocytomas.

  1996cited by this paper
• Platelet-derived Growth Factor Receptor Tyrosine Phosphorylation Requires Protein Geranylgeranylation but not Farnesylation*

  1996cited by this paper
• The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.

  1996cited by this paper
• Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity

  1995cited by this paper
• Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma.

  1995cited by this paper
• Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice

  1995cited by this paper
• Disruption of Oncogenic K-Ras4B Processing and Signaling by a Potent Geranylgeranyltransferase I Inhibitor(*)

  1995cited by this paper
• Polylysine and CVIM Sequences of K-RasB Dictate Specificity of Prenylation and Confer Resistance to Benzodiazepine Peptidomimetic in Vitro(*)

  1995influential reference
• p53 and ras Gene Mutations in Lung Cancer: Implications for Smoking and Occupational Exposures

  1995cited by this paper
• A Non-peptide Mimetic of Ras-CAAX: Selective Inhibition of Farnesyltransferase and Ras Processing (*)

  1995cited by this paper
• Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes (*)

  1995cited by this paper
• Quantification of proteins dissolved in an electrophoresis sample buffer.

  1994cited by this paper
• The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation.

  1994cited by this paper
• Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton

  1994cited by this paper
• Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase.

  1994cited by this paper
• International comparison on ras gene mutations in latent prostate carcinoma

  1994cited by this paper
• Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic.

  1994cited by this paper
• Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes.

  1994cited by this paper
• Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-Ras-transformed Rat-1 cells, but not in untransformed cells.

  1994cited by this paper
• Evidence for abrogation of oncogene-induced radioresistance of mammary cancer cells by hexadecylphosphocholine in vitro.

  1993cited by this paper
• Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor.

  1993cited by this paper
• Genetic evidence for in vivo cross-specificity of the CaaX-box protein prenyltransferases farnesyltransferase and geranylgeranyltransferase-I in Saccharomyces cerevisiae

  1993cited by this paper
• H-ras-1 point mutations in soft tissue sarcomas.

  1993cited by this paper
• Increased radioresistance of ejras‐transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation

  1993cited by this paper
• Oncogene- transformed NIH 3T3 cells display radiation resistance levels indicative of a signal transduction pathway leading to the radiation-resistant phenotype.

  1993cited by this paper
• Differences in radiation-induced micronuclei yields of human cells: influence of ras gene expression and protein localization.

  1993cited by this paper
• Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas.

  1992cited by this paper
• Expression and localization of epidermal growth factor receptors and ras oncogene products in gynecologic tumors.

  1992cited by this paper
• No correlation between ras, c-myc and c-jun proto-oncogene expression and prognosis in advanced carcinoma of cervix.

  1992cited by this paper
• Transformation and radiosensitivity of human diploid skin fibroblasts transfected with activated ras oncogene and SV40 T-antigen.

  1992cited by this paper
• Prevalence of RAS oncogene mutation in head and neck carcinomas.

  1992cited by this paper
• Influence of the H-ras oncogene on radiation responses of a rat rhabdomyosarcoma cell line.

  1992cited by this paper
• Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein

  1992cited by this paper
• Protein isoprenylation and methylation at carboxyl-terminal cysteine residues.

  1992cited by this paper
• The radiosensitivity of human keratinocytes: influence of activated c-H-ras oncogene expression and tumorigenicity.

  1991cited by this paper
• Sequence dependence of protein isoprenylation.

  1991cited by this paper
• Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors.

  1991cited by this paper
• Increased radiation resistance in transformed and nontransformed cells with elevated ras proto-oncogene expression.

  1991cited by this paper
• Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase.

  1991cited by this paper
• Studies on the influence of the presence of an activated ras oncogene on the in vitro radiosensitivity of human mammary epithelial cells.

  1991cited by this paper
• A protein geranylgeranyltransferase from bovine brain: implications for protein prenylation specificity.

  1991cited by this paper
• The role of the H-ras oncogene in radiation resistance and metastasis.

  1990cited by this paper
• Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation.

  1990cited by this paper
• Synergistic effect of the v-myc oncogene with H-ras on radioresistance.

  1990cited by this paper
• Activation of the cellular proto-oncogene product p21Ras by addition of a myristylation signal.

  1989cited by this paper
• Clonogenic cell assay for anchorage‐dependent squamous carcinoma cell lines using limiting dilution

  1989cited by this paper
• Radioresistance induced by oncogenic transformation.

  1989cited by this paper
• High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis.

  1989cited by this paper
• KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.

  1988cited by this paper
• Genetic alterations during colorectal-tumor development.

  1988cited by this paper
• The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation.

  1988cited by this paper
• Somatic deletions and mutations of c-Ha-ras gene in human cervical cancers.

  1988cited by this paper
• Activated human N‐ras oncogene enhances x‐irradiation repair of mammalian cells in vitro less effectively at low dose rate: Implications for increased therapeutic ratio of low dose rate irradiation

  1985cited by this paper
• The p21 ras C-terminus is required for transformation and membrane association

  1984cited by this paper
• Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus.

  1984cited by this paper
• A position 12-activated H-ras oncogene in all HS578T mammary carcinosarcoma cells but not normal mammary cells of the same patient.

  1984cited by this paper
• Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change

  1982cited by this paper
• Mechanism of activation of a human oncogene

  1982cited by this paper
• Gene-Locus Mutation Assays in Diploid Human Lymphoblast Lines

  1980cited by this paper
• Limiting Dilution Analysis

  1979cited by this paper
• Classification of human colorectal adenocarcinoma cell lines.

  1976cited by this paper
• Immunohistology of the antigenic pattern of a continuous cell line from a human colon tumor.

  1975cited by this paper
• CLONAL GROWTH OF MAMMALIAN CELLS IN VITRO

  1956cited by this paper

• Geranylgeranyl transferase inhibitors mitigate intestinal radiation toxicity.

  2025cites this paper
• Targeting the RAS upstream and downstream signaling pathway for Cancer treatment.

  2024cites this paper
• Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer

  2024cites this paper
• KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner

  2023cites this paper
• Evaluation of Potential Predictive Biomarkers for Defining Brain Radiotherapy Efficacy in Non-Small Cell Lung Cancer Patients with Brain Metastases: A Case Report and a Narrative Review

  2023cites this paper
• The Influence of Oncogenic RAS on Chemotherapy and Radiotherapy Resistance Through DNA Repair Pathways

  2022cites this paper
• Protein Farnesylation on Nasopharyngeal Carcinoma, Molecular Background and Its Potential as a Therapeutic Target

  2022cites this paper
• Cooperation between oncogenic Ras and wild-type p53 stimulates STAT non-cell autonomously to promote tumor radioresistance

  2021cites this paper
• Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair

  2021cites this paper
• BRAF mutation correlates with worse local–regional control following radiation therapy in patients with stage III melanoma

  2021cites this paper
• Concurrent use of statins and neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and meta-analysis

  2021cites this paper
• Cooperation between oncogenic Ras and wild-type p53 stimulates STAT non-cell autonomously to promote tumor radioresistance

  2021cites this paper
• Cooperation between oncogenic Ras and p53 stimulates JAK/STAT non-cell autonomously to promote Ras tumor radioresistance

  2020cites this paper
• Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer

  2020cites this paper
• LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy

  2020cites this paper
• Improving the Efficacy of Tumor Radiosensitization Through Combined Molecular Targeting

  2020cites this paper
• Mechanisms of CaaX Protein Processing: Protein Prenylation by FTase and GGTase-I

  2020cites this paper
• National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer

  2019cites this paper
• Altering the response to radiation: radiosensitizers and targeted therapies in pancreatic ductal adenocarcinoma: preclinical and emerging clinical evidence.

  2018cites this paper
• Integrating Biological Covariates into Gene Expression-Based Predictors of Radiation Sensitivity

  2017cites this paper
• TAT-RasGAP317–326 Enhances Radiosensitivity of Human Carcinoma Cell Lines In Vitro and In Vivo through Promotion of Delayed Mitotic Cell Death

  2017cites this paper
• Profiling of a panel of radioresistant prostate cancer cells identifies deregulation of key miRNAs

  2017cites this paper
• The Nogo-B receptor promotes Ras plasma membrane localization and activation

  2016cites this paper
• RhoGTPases - A novel link between cytoskeleton organization and cisplatin resistance.

  2015cites this paper
• Future Directions in Pancreatic Cancer Therapy

  2015cites this paper
• A comprehensive analysis of radiosensitization targets; functional inhibition of DNA methyltransferase 3B radiosensitizes by disrupting DNA damage regulation

  2015cites this paper
• 7.06 – Tumor Radiation Biology

  2014cites this paper
• Everolimus sensitizes Ras-transformed cells to radiation in vitro through the autophagy pathway.

  2014cites this paper
• Radiotherapy for Rectal Cancer: An Exploration of Factors Associated with Symptoms and Tumour Response

  2014cites this paper
• The role of RhoD in actin dynamics, receptor trafficking and cancer cell migration

  2013cites this paper
• Transformation by HrasG12V is Consistently Associated with Mutant Allele Copy Gains and is Reversed by Farnesyl Transferase Inhibition

  2013cites this paper
• The Clinical Significance of Mutations in Colorectal Cancer

  2013cites this paper
• Molecular biomarkers as predictors of response to neoadjuvant chemoradiation therapy in rectal cancer

  2013cites this paper
• Farnesyltransferase Inhibitors

  2012cites this paper
• The molecular basis of chemoradiosensitivity in rectal cancer:implications for personalized therapies

  2012cites this paper
• Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer

  2012cites this paper
• Title : Co-Targeting MAPK and PI 3 K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer Running Title : MEK and Akt pathway radiosensitization in pancreatic cancer

  2012cites this paper
• Dapson in Heterocyclic Chemistry Part VI: Synthesis and Molecular Docking of Some Novel Sulfonebiscompounds of Expected Anticancer Activity

  2012cites this paper
• Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas

  2011cites this paper
• treatment for hematologic malignancies? Targeting the Ras signaling pathway: a rational, mechanism-based

  2011cites this paper
• Evaluation of focal adhesion kinase as a novel radiosensitising target

  2010cites this paper
• Enhancing Gene Expression Signatures in Cancer Prediction Models: Understanding and Managing Classification Complexity

  2010influential citation
• Ras-related small GTPases RalA and RalB regulate cellular survival after ionizing radiation.

  2010cites this paper
• Ionizing Radiation as a Carcinogen

  2010cites this paper
• The Ras-related small GTPases RalA and RalB regulate cellular survival after ionizing radiation

  2010cites this paper
• Andrographolide sensitizes Ras-transformed cells to radiation in vitro and in vivo.

  2010cites this paper
• Targeting the mevalonate pathway for improved anticancer therapy.

  2009cites this paper
• On the path to seeking novel radiosensitizers.

  2009cites this paper
• Molecular targets for tumor radiosensitization.

  2009cites this paper
• Membrane proteins and membrane proteomics

  2008cites this paper
• RAS: Target for Cancer Therapy

  2008cites this paper
• Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma.

  2008cites this paper
• Clinical target promiscuity: lessons from ras molecular trials

  2008cites this paper
• SEARCHING FOR RADIOSENSITIZERS: DEVELOPMENT OF A NOVEL ASSAY AND HIGH-THROUGHPUT SCREENING

  2008cites this paper
• Downregulation of PAR‐4, a pro‐apoptotic gene, in pancreatic tumors harboring K‐ras mutation

  2008cites this paper
• Chemoprevention of Pancreatic Cancer: Characterization of Par-4 and its Modulation by 3,3′ Diindolylmethane (DIM)

  2008cites this paper
• Enhancement of tumor radioresponse by wortmannin in C3H/HeJ hepatocarcinoma.

  2007cites this paper
• Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells.

  2007cites this paper
• Development of farnesyl transferase inhibitors as anticancer agents: current status and future

  2007cites this paper
• Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme.

  2007cites this paper
• Targeted therapies for non-small cell lung cancer.

  2007cites this paper
• Radiosensitization and modulation of p44/42 mitogen-activated protein kinase by 2-Methoxyestradiol in prostate cancer models.

  2007cites this paper
• The ras signalling pathway as a target in cancer therapy.

  2007cites this paper
• Rho GTPases: promising cellular targets for novel anticancer drugs.

  2006cites this paper
• Mechanism and role of EGFR Tyrosine Kinase Inhibition in radiation response of human tumor and normal cells

  2006cites this paper
• HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway.

  2006cites this paper
• Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines

  2006cites this paper
• Anti-cancer therapy: targeting the mevalonate pathway.

  2006cites this paper
• Controversies related to the use of agents with a potential anticancer activity

  2006cites this paper
• Lonafarnib in cancer therapy

  2006cites this paper
• Assessing the consequences of hurricane-induced fragmentation of mangrove forest on habitat and nekton in Big Sable Creek, Florida

  2006cites this paper
• Ras Signaling Pathways and Farnesyltransferase Inhibitors

  2006cites this paper
• Regulation of transcription and analysis of drug targets in lymphoma and myeloma cells

  2006cites this paper
• Tumor-Directed Radiation and the Immunotoxin SS1P in the Treatment of Mesothelin-Expressing Tumor Xenografts

  2006cites this paper
• Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation.

  2006cites this paper
• MOLECULAR TARGETS FOR RADIOSENSITIZATION

  2006cites this paper
• Molecular targets for altering radiosensitivity: lessons from Ras as a pre-clinical and clinical model.

  2005cites this paper
• Novel Substances in the Treatment of Lung Cancer for the Radiation Oncologist

  2005cites this paper
• Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras.

  2005cites this paper
• [Development of farsenyl transferase inhibitors as anticancer agents].

  2005cites this paper
• Développement des inhibiteurs de farnésyl transférase comme agents anticancéreux

  2005cites this paper
• Oncogenic H-Ras up-regulates expression of Ku80 to protect cells from gamma-ray irradiation in NIH3T3 cells.

  2005cites this paper
• Farnesylated RhoB inhibits radiation-induced mitotic cell death and controls radiation-induced centrosome overduplication

  2005cites this paper
• HMG-CoA reductase inhibitors (statins) as anticancer drugs (review).

  2005cites this paper
• Effect of the Farnesyl Transferase Inhibitor L-744,832 on the Colon Cancer Cell Line DLD-1 and Its Combined Use with Radiation and 5-FU

  2005cites this paper
• Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines.

  2005cites this paper
• [Targeted therapies and radiotherapy].

  2005cites this paper
• Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer.

  2005cites this paper
• Farnesyltransferase inhibitor effects on prostate tumor micro‐environment and radiation survival

  2005influential citation
• Radiation Sensitization by Inhibition of Activated Ras

  2004cites this paper
• Biologic premises of combined radiation therapy and chemotherapy in lung cancer.

  2004cites this paper
• The role of Raf-1 in radiation resistance of human hepatocellular carcinoma Hep G2 cells.

  2004cites this paper
• A Phase I Trial of the Dual Farnesyltransferase and Geranylgeranyltransferase Inhibitor L-778,123 and Radiotherapy for Locally Advanced Pancreatic Cancer

  2004cites this paper
• Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.

  2004cites this paper
• Differential effects of prenyl pyrophosphates on the phosphatase activity of phosphotyrosyl protein phosphatase.

  2004cites this paper
• The influence of Ras pathway signaling on tumor radiosensitivity

  2004cites this paper
• Altered molecular pathways in gliomas: an overview of clinically relevant issues.

  2004cites this paper
• Farnesyltransferase inhibitors: recent advances

  2004cites this paper
• Perspectives on farnesyl transferase inhibitors in cancer therapy.

  2004cites this paper
• Can mouse models for brain tumors inform treatment in pediatric patients?

  2004cites this paper